Clinical Trials Logo

Clinical Trial Summary

The study will test an app and web-delivered intervention designed to improve glycemic control (HbA1c) among young adults with Type 1 diabetes. All participants will receive the "core" digital intervention, the SweetGoals app, focused on self-monitoring and goal setting. Efficacy of two independent intervention components (incentives for adherence and web health coaching) will be tested


Clinical Trial Description

ASSIGNMENT OF PARTICIPANTS: Interested participants will download the SweetGoals app. Once all screening procedures are complete, including A1c verification via the mail in test kit, research staff will schedule a web video meeting to (1) randomize participants and inform them of their intervention condition assignment; (2)assist participants in setting up their Glooko account and uploading their devices and orient them to the Glooko data visualization hub; and (3) download the Glooko mobile app, which may be used by all participants and into which participants without a Glooko compatible pump will enter carb counts. INTERVENTION DELIVERY: All participants will receive the core intervention, the SweetGoals app. Those assigned to Incentives will receive the app plus incentives for meeting adherence goals. Those assigned to Coaching will receive web health coaching to increase motivation and skill in self-management as described below. DIABETES CARE FOR ALL PARTICIPANTS: Participants in all conditions will receive ongoing treatment for type 1 diabetes from their current medical provider. Report of a visit within the past 6 months is a study inclusion criterion. Study staff will not provide medical care or intervention. All participants will receive information about recommendations for medical care related to diabetes (e.g., quarterly visits and A1c assessment, consistent with Standards of Medical Care in Diabetes). Informational links will be provided within SweetGoals for various online resources addressing T1D educational topics. CORE INTERVENTION FOR ALL PARTICIPANTS: SWEETGOALS APP All participants will receive the SweetGoals app, an automated intervention that sets weekly self-management goals and provides weekly feedback. The SweetGoals app will be implemented and delivered using the MobileCoach app platform, which runs on both Android and iOS systems. The SweetGoals app sends weekly reminders to upload devices, retrieves device data via the Glooko API, applies decision rules to evaluate daily and weekly goals, and sends weekly feedback messages about goal adherence and encouragement about adherence in the upcoming week. Diabetes Self-Management Goals. Glooko stores multiple variables that are used to evaluate the glucose monitoring and mealtime goals. Across both glucose monitoring and mealtime target behaviors, we use a similar structure to the goals to promote ease of remembering the goals and communication with participants. Specifically, regardless of the devices used or the target (glucose monitoring or mealtime behaviors) there is a daily adherence goal, and there is a weekly goal of meeting the daily goal on >5 days each week. These weekly goals were selected to promote high consistency in mealtime glucose monitoring and carb counting. Each week, participants will be asked to set personal goals for the next week for the number of days they think they can meet each daily goal. Each week they will receive a message stating the number of days on which they met each goal, how that compared to their personal goal, and whether they met the ultimate weekly goal (met daily goal >5 days per week). Glucose monitoring goals. Each participant will receive a device-specific (glucometer vs. CGM) daily goal based on the device they use to monitoring their glucose levels, and the ultimate weekly goal for all participants is to meet the daily goal on at least 5 days per week. For participants who use a glucometer only, the daily self-monitoring of blood glucose (SMBG) goal is >5 checks, each >2 hours from another check. For participants who use CGM, the CGM wear time goal is 80% of expected values each day. Expected values per day are based on the device-specific check frequency (e.g., every 5 mins for Dexcom G6). We selected this cutoff to reflect clinically necessary glucose monitoring frequency, but also allow for legitimate disconnect time (sports, leisure activities) and sensor changes. Mealtime goals. Each participant will receive daily goals specific to their insulin delivery method (pump vs. MDI). Participants will be asked to check their glucose before they eat (if they use a glucometer only, not CGM). Participants who use a Glooko compatible pump will only need to use their pump to document the mealtime goals. If they use a pump+glucometer combination that requires manual entry of the glucose value into the pump, they must complete the glucose check and that manual entry no longer than 30 minutes before the carb entry to receive credit for meeting the mealtime goal. If they use a pump+CGM or other meter that transfers the glucose value to the pump without manual entry, no manual entry is necessary. If they use MDI (no insulin pump), they will use the Food event screen to enter their carb counts in the Glooko smartphone app. When each participant's Glooko data are retrieved, our algorithm evaluates whether or not there is a valid glucose value within 30 minutes prior to each carb entry. The daily mealtime target is 3 paired glucose level/carb count values. INCENTIVE COMPONENT In addition to using the SweetGoals app, participants assigned to Incentives will also receive incentives for meeting goals. Incentives to improve adherence to glucose monitoring and mealtime behaviors that support appropriate insulin bolusing are paid weekly from weeks 1-11, then fade in frequency from weeks 12-25, a procedure used to promote long lasting improvements in adherence and A1c. In the fading phase, incentives are paid at increasing time intervals (i.e., 2,3,4 then 5-week delays; paid at weeks 13, 16, 20, 25). For meeting daily and weekly goals, participants can earn the following incentives: (1) $1 for each day meeting glucose monitoring goal. (maximum=$7 per week); (2) $5 per week bonus for meeting the glucose monitoring goal 6 or 7 days to promote consistent weekly glucose monitoring. (maximum=$5 per week) (3) $1 for every day with >3 properly timed glucose value/carb entry pairs (maximum=$7 per week); (4) $5 per week bonus for meeting the mealtime goal 6 or 7 days to promote consistent weekly glucose checking and carb counting at mealtime. (maximum=$5 per week). Total earnings possible each week are $24 (~$3.50 per day). The maximum earnings for all goals are $600 across 25 weeks. Research staff will load earned incentives on reloadable prepaid MasterCards. WEB HEALTH COACHING COMPONENT: Participants assigned to coaching will also receive 15 Web Health Coaching sessions by a bachelors-level health coach. These coaching sessions are designed to promote effective self-management of diabetes. Coaching sessions are held weekly from weeks 1-11, then fade over the second half of the intervention with 4 sessions held during weeks 12-25 (weeks 13, 16, 20, and 25). Sessions 1-7 are 30 minutes each, as new material is introduced and practiced. Sessions 8-15 are 15 minutes each, as problem solving skills are practiced and applied to new challenges identified by participants. Coaching will be completed using Zoom, an online HIPAA compliant web conference system. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04646473
Study type Interventional
Source Trustees of Dartmouth College
Contact
Status Active, not recruiting
Phase N/A
Start date April 29, 2021
Completion date April 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02914886 - Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Phase 4
Completed NCT02897557 - Insulet Artificial Pancreas Early Feasibility Study N/A